ferric(III)carboxymaltose — Competitive Intelligence Brief

ferric(III)carboxymaltose (ferric(III)carboxymaltose) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Iron replacement agent. Area: Hematology.

marketed Iron replacement agent Iron metabolism / transferrin-mediated iron transport Hematology Small molecule

Target snapshot

ferric(III)carboxymaltose (ferric(III)carboxymaltose) — Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Ferric carboxymaltose is an iron replacement therapy that delivers ferric iron complexed with carboxymaltose to replenish depleted iron stores and treat iron deficiency anemia.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ferric(III)carboxymaltose TARGET	ferric(III)carboxymaltose	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	marketed	Iron replacement agent	Iron metabolism / transferrin-mediated iron transport
Vifor and EPO	Vifor and EPO	Kunshan First People's Hospital Affiliated to Jiangsu University	marketed	Iron replacement agent and erythropoiesis-stimulating agent (ESA)	Iron (ferric ion) and erythropoietin receptor (EPOR)
Iron Sucrose IV	Iron Sucrose IV	CN NGANOU-GNINDJIO, MD, MSc	marketed	Iron replacement agent	Transferrin receptor (indirect); iron supplementation
Ferric Carboxymaltose (FCM)	Ferric Carboxymaltose (FCM)	American Regent, Inc.	marketed	Intravenous iron replacement agent	Iron (Fe³⁺) delivery; transferrin and ferritin binding
Generic sodium ferric gluconate	Generic sodium ferric gluconate	University of Maryland, Baltimore	marketed	Iron replacement agent	Iron (Fe3+) delivery; hemoglobin and myoglobin synthesis
i.v. iron sucrose	i.v. iron sucrose	J. Uriach and Company	marketed	Iron replacement agent
Brand sodium ferric gluconate	Brand sodium ferric gluconate	University of Maryland, Baltimore	marketed	Iron replacement agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Iron replacement agent class)

1. University of Maryland, Baltimore · 2 drugs in this class
2. Ain Shams University · 1 drug in this class
3. American Regent, Inc. · 1 drug in this class
4. Azad Pharma AG · 1 drug in this class
5. CN NGANOU-GNINDJIO, MD, MSc · 1 drug in this class
6. China-Japan Friendship Hospital · 1 drug in this class
7. Hallym University Medical Center · 1 drug in this class
8. J. Uriach and Company · 1 drug in this class
9. JW Pharmaceutical · 1 drug in this class
10. Prince of Wales Hospital, Shatin, Hong Kong · 1 drug in this class